The role of UFT in advanced gastric cancer

Background: Advanced gastric cancer has a poor prognosis, with a relative 5-year survival rate of 7%-27%. Chemotherapy, which improves overall survival (OS) and quality of life, is the main treatment option. Although numerous regimens have been investigated, there is no standard treatment. Combination chemotherapy, however, is associated with a significant survival benefit compared with monotherapy and i.v. 5-fluorouracil (5-FU) is one of the most widely used agents. UFT (tegafur-uracil) has similar efficacy to continuous infusion 5-FU with improved tolerability and is more convenient for patients

Modeling of gas demand using degree-day concept: Case study for Ankara

The demand for natural gas is rapidly increasing in Turkey as it is in the rest of the world. However, natural gas reserves and production are rather limited in Turkey. The bulk of the Turkish gets demand is met by imports. Russia currently accounts for 69% of Turkey's gas supplies. Physical shortages might occur; supplies for industrial production and household consumption could temporarily run short. Also, fluctuations in consumption might occur due to climatic reasons or peak daily industrial energy demand Underground gas storage is a necessity in order to regulate these seasonal, daily and hourly fluctuations. In order to effectively design and utilize underground gas storage, it is necessary to identify the market requirements

An open-label trial to assess the safety of regorafenib in Turkish patients with metastatic colorectal cancer (mCRC) that progressed on standard therapy (REGARD)

ESMO 17th World Congress on Gastrointestinal Cancer -- JUL 01-04, 2015 -- Barcelona, SPAINWOS: 000357047400123…ESM

THE EFFICACY OF A 5-DRUG ANTIEMETIC COMBINATION DURING CHEMOTHERAPY REGIMENS CONTAINING CISPLATIN OR CYCLOPHOSPHAMIDE DOXORUBICIN

A five-drug combination, including metoclopramide, thiethylperazine, diphenhydramine, dexamethasone, and diazepam, was given to 32 patients during three consecutive treatments with chemotherapy. Eighteen patients (group A) were treated with a cisplatin-containing regimen, and 14 patients (group B) were treated with a cyclophosphamide- and doxorubicin-containing chemotherapy. In group A, complete responses were lower on the first day than on the second and third days (P < 0.015 and P < 0.041, respectively), during the first and second courses. The five-drug antiemetic regimen seems safe and effective. These results show that clinical trials that evaluate antiemetic efficacy in cisplatin-containing chemotherapy regimens should evaluate at least two consecutive courses